VahatiCor Secures $23M Series B Financing to Advance A-Flux Reducer for Coronary Microvascular Dysfunction

Chest Pain but No Blockage Found? This “Silent Heart Disease” Finally, there is a new solution.

“No Blocked Vessels in Heart Examination, Yet Persistent Chest Tightness and Pain”—— This is not being finicky, it could be coronary microvascular disease (CMVD) is to blame. This is referred to as “The Silent Heart Killer” The disease, which is affecting tens of millions of people worldwide, poses an even greater risk to female patients than to males. 1.45 Times.

Recently, the medical technology company VahatiCor A financing announcement has brought hope to the patient community: its development of A-Flux Reducer System Completed 2300 Million USD B This round of financing, with the oversubscribed funds, will accelerate the clinical trials and market launch process of this minimally invasive device.

I.400 The Dilemma of Thousands of Americans: Untreatable “Microvascular Traffic Jam”

CMVD The special feature is that the main arteries of the patient's heart are completely unobstructed, but the tiny vessels responsible for myocardial blood supply have developed functional disorders. This leads to myocardial ischemia and hypoxia, causing recurrent angina pectoris, and in severe cases, even inducing myocardial infarction and heart failure.

More distressing is:

1.In the United States, approximately 400 Thousands of patients are troubled by it, in China INOCA(Non-obstructive coronary ischemia) prevalence is approximately 20%, women are the main high-risk group;

2.Female INOCA The incidence of cardiovascular adverse events in patients is actually male. 4 Times;

3.Existing drugs are ineffective for more than half of patients, and no therapy can directly improve coronary flow reserve.

“Obviously very ill, but no effective treatment can be found”—— This is exactly CMVD The common pain points of patients have also made this field a blue ocean for medical investment.

2. Hourglass Shape “Blood Flow Regulator”: To the heart microvessels “Unblocking”

VahatiCor The A-Flux Reducer System,堪称针对 CMVD The “Precision Strike” Solution. The core design of this innovative device is full of ingenuity:

✅ Shaped like an hourglass: A self-expanding frame braided from nickel-titanium alloy, forming an hourglass shape that is narrow in the middle and wider at both ends after implantation;

✅ Minimally Invasive Implantation: Through a jugular vein interventional procedure, the device is delivered to the coronary sinus without the need for thoracotomy;

✅ The principle is very ingenious.: By controllably narrowing the coronary sinus, it forces blood to redistribute, allowing the ischemic myocardial region to receive sufficient perfusion and relieving chest pain at its root cause;

✅ Safe and Secure: The design is repositionable. Compared with Johnson & Johnson's similar stainless steel devices, the self-expanding properties of nitinol make the surgery safer and more adaptable.

“This is a major breakthrough for a large and underserved patient population.” Lead Investor S3 Ventures Managing Director Brian R. Smith It is emphasized that the device's advantages in safety and efficacy are expected to make it a leader in coronary sinus therapy.

3. Star Capital Endorsement:2300 Million Dollars to Boost Clinical Implementation

This round of financing was led by S3 Ventures Leading the investment, the parent company of the Da Vinci surgical robot Intuitive Surgical Under its umbrella Intuitive Ventures Strategic follow-up investment. Notably,S3 Ventures Previously, it has successfully incubated multiple vascular treatment device companies, and Intuitive Ventures The entry of VahatiCor, Inc. further highlights the industry's recognition of this technology.

The funds will be mainly used for:

• Advance SERRA-I Early Feasibility Study: In 6 Clinical Center Recruitment 30 Patients, to verify the safety and effectiveness of the device;

• Optimize equipment engineering design to prepare for subsequent pivotal clinical trials.

VahatiCor Co-Founder Marwan Berrada-Sounni Indicates:“This funding will help us accelerate the delivery of this breakthrough therapy to millions of people.CMVD Troubled patients.”

4. The Warmth of Medical Technology: Beyond Financing Figures

2300 Million-dollar financing behind, it is medical technology's “Rare Diseases” The attention. For a long time,CMVD Due to complex diagnosis and lack of treatment options, it has become a neglected medical gap. And A-Flux Reducer The emergence of the system not only fills a technical gap but also rewrites the survival status of patients.

Currently, the device has entered the early clinical trial stage. If progress is smooth, this minimally invasive device is expected to be available in the future. 3-5 Approved for marketing within the year, becoming CMVD Patient's “Straw of Life”For those patients who have been tormented by chest pain for a long time and have not responded to drug treatment, this is undoubtedly the most anticipated medical innovation.

From No Cure to Precision Minimally Invasive Treatment: Advances in Medical Technology Are Rewriting the History of Disease Treatment.2300 Million-dollar financing is not only a recognition of a technology, but also a response to the needs of tens of millions of patients.

Are there any similar ones around you? “Chest Pain of Unknown Origin” Patients? Welcome to share your thoughts in the comment section, and let's pay attention to this medical innovation that can change the fate of countless people~